Anyone who has scrolled past health headlines in the past year knows that Ozempic, Mounjaro, and their weight-loss cousins are seemingly everywhere. The promises are big, but the real picture is more layered — impressive clinical results, genuine side effects, and hard questions about who stays on these drugs and why. Here is what the latest data and expert sources actually tell us about where obesity treatment stands right now.

4 related posts

Eli Lilly experimental drug weight loss: 28% over 18 months ·
Novo Nordisk launches Wegovy in UK: 2025 ·
Retatrutide expected approval: Potential 2026 ·
Ozempic and Mounjaro comparison focus: Most searched

Quick snapshot

1Confirmed facts
  • Eli Lilly experimental drug achieved 28% weight loss over 18 months (KFF Health News)
  • Novo Nordisk launched Wegovy in the UK in 2025 (HealthCentral)
  • Mounjaro carries an FDA boxed warning for thyroid cancer risk (Medical News Today)
2What’s unclear
3Timeline signal
4What’s next
  • Next-gen obesity drugs entering late-stage trials (Medical News Today)
  • NHS weight management injections expanding access (KFF Health News)
  • More data on lean mass loss and long-term safety (KFF Health News)

The table below captures key details across the leading obesity drugs and pipeline candidates.

Key facts at a glance across the leading obesity drugs and pipeline candidates.
Drug / Entity Key detail Source
Eli Lilly obesity drug weight loss 28% over 18 months KFF Health News
Ozempic approval Approved for type 2 diabetes, off-label for weight loss HealthCentral
Mounjaro approval Approved for type 2 diabetes, also for weight loss (brand Zepbound) Medical News Today
Retatrutide development Phase 3 trials, potential 2026 launch PMC / RAND analysis
NHS weight management injections Wegovy available in UK from 2025 HealthCentral

What is the latest news on weight-loss drugs?

The biggest headline in obesity drug news today comes from Eli Lilly’s experimental drug, which helped patients lose 28% of their body weight over 18 months according to trial data covered by KFF Health News. That figure outpaces what existing therapies like Ozempic and Mounjaro have shown in head-to-head comparisons, though the trial population and duration matter when judging real-world impact.

Novo Nordisk launched Wegovy in the UK in 2025, making it available through the NHS for weight management, as reported by HealthCentral. The UK rollout signals a shift toward publicly funded access to GLP-1 drugs, though supply constraints and eligibility criteria remain active issues.

  • Eli Lilly retatrutide phase 3 trials are ongoing, with data expected through 2025 (PMC / RAND analysis)
  • Next-generation drugs targeting multiple hormone receptors are in development (Medical News Today)
  • 11.8% of U.S. adults reported using GLP-1 agonists in a 2025 survey (PMC / RAND analysis)
Bottom line: The obesity drug pipeline is moving fast — Eli Lilly’s candidate leads on efficacy numbers, but real-world access and long-term data still trail behind the headlines. For patients: the most effective drug on paper may not be the best fit for your body or your wallet. For prescribers: watch for ongoing trial results before switching patients.
The upshot

The 28% weight loss figure from Eli Lilly’s trial is the strongest efficacy signal yet, but it comes from a mid-stage study. The real test will be phase 3 replication and long-term safety data, especially for older adults who make up the fastest-growing segment of GLP-1 users.

Which is better Ozempic or Mounjaro?

Ozempic (semaglutide) and Mounjaro (tirzepatide) are both GLP-1 receptor agonists, but they are not identical. Mounjaro also targets the GIP receptor, which appears to drive greater weight loss in clinical trials. According to Medical News Today, Mounjaro has shown higher efficacy for weight reduction compared with semaglutide in head-to-head studies, though both drugs share a similar side effect profile dominated by gastrointestinal issues.

Five key differences, one pattern: Mounjaro tends to produce greater weight loss, but both drugs challenge patient tolerance with nausea, diarrhea, and vomiting.

Feature Ozempic (semaglutide) Mounjaro (tirzepatide)
Drug class GLP-1 receptor agonist GLP-1 + GIP receptor agonist
Approved for Type 2 diabetes (+ off-label weight loss) Type 2 diabetes (+ weight loss as Zepbound)
Common side effects Nausea, diarrhea, constipation, vomiting (HealthCentral) Nausea, diarrhea, appetite loss, slowed stomach emptying (Medical News Today)
Serious risks Pancreatitis, kidney injury, thyroid tumors Thyroid cancer (FDA boxed warning), pancreatitis, gallbladder problems
Weight loss efficacy ~15% average in trials ~20-25% average in trials

The pattern: efficacy differences matter less than patient tolerance and long-term adherence.

Is Mounjaro better than Ozempic?

  • For weight loss alone: Mounjaro has the edge in clinical trials (Medical News Today)
  • For diabetes management: both are effective, but Ozempic has longer real-world data (HealthCentral)
  • For side effect tolerance: roughly similar — about half of users report nausea, one-third report diarrhea (PMC / RAND analysis)
  • For cost and access: depends on insurance and regional approvals
Bottom line: Mounjaro outperforms Ozempic on weight loss in trials, but “better” depends on individual tolerance, cost, and treatment goals. Patients prioritizing maximum weight reduction may prefer Mounjaro; those wanting longer safety data and similar glucose control may lean toward Ozempic.

What organ is Ozempic hard on?

Ozempic places the most strain on the digestive system and, in a smaller number of cases, the pancreas and kidneys. According to HealthCentral, the most common side effects are abdominal pain, constipation, diarrhea, nausea, and vomiting — all gastrointestinal. More serious but less common risks include pancreatitis and acute kidney injury, as noted by Medical News Today for the related drug class.

  • Pancreas: pancreatitis is a known serious adverse event (Medical News Today)
  • Kidneys: acute kidney injury has been reported, especially in dehydrated patients
  • Thyroid: Mounjaro carries an FDA boxed warning for thyroid C-cell tumors (Medical News Today)
  • Gallbladder: gallbladder disease, including cholecystitis, has been reported

Who should not take Mounjaro?

Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in those with Multiple Endocrine Neoplasia syndrome type 2, according to the FDA boxed warning cited by Medical News Today. It is also not recommended for people with severe gastrointestinal disease, including gastroparesis, because the drug slows stomach emptying and can worsen symptoms.

How often should I poop on Ozempic?

There is no single answer — bowel changes vary widely. Constipation and diarrhea are both listed as common side effects by HealthCentral. Some patients experience constipation that lasts days, while others have frequent loose stools. About one-third of GLP-1 users in the RAND survey analysis reported diarrhea. Staying hydrated and adjusting fiber intake can help, but persistent changes warrant a conversation with a prescriber.

What to watch

For older adults on Ozempic or Mounjaro, the combination of slowed digestion, reduced appetite, and dehydration risk can lead to acute kidney injury faster than in younger patients. Monitoring hydration and kidney function is not optional — it is a safety baseline.

Bottom line: The gut takes the biggest hit with GLP-1 drugs, but the pancreas, kidneys, and thyroid carry less common but more serious risks. Patients with a history of pancreatitis, kidney disease, or thyroid cancer should discuss alternatives with their doctor before starting.

When will retatrutide be available?

Retatrutide, Eli Lilly’s triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors, is still in phase 3 clinical trials with expected completion in 2025. If results are positive, a New Drug Application could follow, with potential FDA approval in 2026, according to data tracked by PMC / RAND analysis.

The drug has shown up to 28% weight loss in phase 2 data — a figure that, if replicated in larger trials, would make it the most potent obesity drug yet. But the gap between phase 2 excitement and phase 3 reality has humbled many drug candidates before.

What is the new weight-loss drug in 2026?

  • Retatrutide (Eli Lilly) — triple-receptor agonist, potential approval 2026 (PMC / RAND analysis)
  • Orforglipron (Eli Lilly) — oral GLP-1 agonist, phase 3 ongoing
  • Danuglipron (Pfizer) — oral GLP-1 agonist, reformulated after tolerability issues
  • MariTide (Amgen) — dual GLP-1/GIP antibody, monthly dosing

Seven candidates in late-stage development, one pattern: the next wave of obesity drugs targets multiple hormone receptors to improve efficacy while trying to reduce injection frequency or move to oral forms.

The trade-off: more receptors mean more unknowns about long-term safety in diverse populations.

The trade-off

More receptors mean more efficacy, but also more unknowns. Triple agonism may amplify weight loss, but it could also amplify side effects. Older adults and those with polypharmacy regimens will need dedicated safety data before these drugs see widespread use.

Bottom line: Retatrutide could land in 2026, but that timeline depends on phase 3 results and regulatory review. For patients: do not wait for a specific drug that is not yet approved. For investors: the pipeline is crowded, and differentiation will come from safety data, not just efficacy numbers.

Why are older people quitting Ozempic?

A growing body of evidence suggests that older adults are stopping GLP-1 drugs like Ozempic at higher rates than younger users. According to KFF Health News, up to 20% of patients experience gastrointestinal problems severe enough to consider discontinuation. Older adults are more prone to nausea, vomiting, and diarrhea — the very side effects that drive people to stop.

The RAND survey analysis found that GLP-1 use was highest among adults ages 50 to 64, with one in five women in that age group reporting use. But high usage does not equal high adherence — digestive intolerance, cost concerns, and the burden of injections all contribute to dropout.

The paradox

The patients who could benefit most from GLP-1 drugs — older adults with obesity and diabetes — are also the ones most likely to stop taking them. Nausea and vomiting are not minor inconveniences; they are the top reason seniors quit, and the muscle loss that can accompany rapid weight loss raises additional concerns for frailty and fall risk.

Why seniors stop taking GLP-1 diabetes drugs?

  • Gastrointestinal side effects (nausea, vomiting, diarrhea) — most common reason (KFF Health News)
  • Medication interactions with existing regimens (HealthCentral)
  • Cost and insurance coverage changes (KFF Health News)
  • 34% to 45% of weight lost may be lean mass, not fat — a concern for older adults (KFF Health News)

The implication: adherence support for older adults must address GI tolerance and muscle preservation, not just efficacy.

Bottom line: Older adults quit GLP-1 drugs primarily because of digestive side effects and concerns about muscle loss. For prescribers: starting at a lower dose, slowing titration, and monitoring hydration and lean mass can improve adherence. For patients: report side effects early — dose adjustment may be all that is needed.

Timeline signal

  • 2023-2024: Ozempic and Mounjaro gain widespread popularity for weight loss; supply shortages emerge (HealthCentral)
  • 2025: Novo Nordisk launches Wegovy in UK; Eli Lilly retatrutide phase 3 data expected; 11.8% of U.S. adults report GLP-1 use (PMC / RAND analysis)
  • 2026: Potential FDA approval of retatrutide and other next-generation drugs (PMC / RAND analysis)

Clarity check

Confirmed facts

  • Eli Lilly experimental drug achieved 28% weight loss over 18 months (KFF Health News)
  • Wegovy launched in UK by Novo Nordisk (HealthCentral)
  • Ozempic can cause pancreatitis, kidney issues, and GI side effects (Medical News Today)
  • Mounjaro carries FDA boxed warning for thyroid cancer (Medical News Today)
  • 11.8% of U.S. adults used GLP-1 agonists in 2025 (PMC / RAND analysis)
  • About 35-45% of weight lost on GLP-1 drugs may be lean mass (KFF Health News)

What’s unclear

  • Exact availability date of retatrutide (PMC / RAND analysis)
  • Long-term cardiovascular safety of GLP-1 drugs in seniors (KFF Health News)
  • Impact of insurance coverage on patient adherence over time (KFF Health News)
  • Real-world rates of muscle loss with different GLP-1 drugs

Expert perspectives

“The most commonly reported side effects are gastrointestinal — nausea, sometimes vomiting, bloating, and diarrhea. As many as 20% of patients may experience problems significant enough to consider stopping the medication.”

— Clinician quoted in KFF Health News report on GLP-1 use in older adults

“About half of GLP-1 users reported nausea and about one-third reported diarrhea. Most participants who reported nausea or vomiting said their symptoms occurred at least sometimes.”

— RAND survey analysis published via PMC on GLP-1 side effect prevalence

“For older adults, the goal of GLP-1 treatment is often better diabetes control, mobility, and quality of life — not only reducing the number on the scale.”

— HealthCentral analysis of age-related considerations for Ozempic use

What this means for you

The next wave of obesity drugs will bring higher efficacy, more options, and tougher decisions. For patients in the UK and US weighing whether to start or continue a GLP-1 drug, the choice revolves around one question: does the expected benefit outweigh the real risk of GI side effects and muscle loss? For the NHS and Medicare, the budget must cover not just the drugs but also the monitoring — hydration, kidney function, lean mass, and adherence support — or the expensive prescriptions will go unused.

Additional sources

sokolovelaw.com

Don't miss these

Frequently asked questions

Can I take Ozempic for weight loss if I do not have diabetes?

Yes, but only off-label unless prescribed as Wegovy (semaglutide for weight loss) or Zepbound (tirzepatide for weight loss). Ozempic is FDA-approved for type 2 diabetes, but many prescribers use it off-label for weight management. Discuss the risks and benefits with your doctor.

What is the cost of Mounjaro with insurance?

Costs vary widely by plan. According to KFF Health News, Medicare Part D plans may pay around $274 for the drug in one scenario, with beneficiaries paying $68.50 out of pocket with 25% coinsurance. Private insurance costs depend on formulary tier and deductibles.

Are there any natural alternatives to GLP-1 drugs?

No supplement or natural product replicates the mechanism of GLP-1 agonists. Lifestyle interventions — diet, exercise, and behavioral support — remain the first-line approach for weight management and can produce meaningful results, but they are not pharmacological alternatives.

How long does it take to see weight loss results on Ozempic?

Most patients see initial weight changes within 4 to 8 weeks, but significant results typically take 12 to 24 weeks, depending on dose titration. Weight loss of 5-10% of body weight is common by 6 months of consistent use, according to clinical trial data cited by HealthCentral.

What are the long-term side effects of weight-loss injections?

Long-term data beyond 2-3 years remains limited. Known risks include pancreatitis, kidney injury, gallbladder disease, and thyroid tumors. The FDA continues to monitor adverse events. Patients should have regular follow-ups including blood work and kidney function tests, especially if taking other medications.

Do weight-loss drugs interact with other medications?

Yes. GLP-1 drugs slow gastric emptying, which can affect the absorption of oral medications. According to Medical News Today, this is particularly relevant for drugs with a narrow therapeutic index. Patients on blood thinners, thyroid hormone, or oral contraceptives should discuss timing adjustments with their pharmacist.

Is it safe to use Ozempic during pregnancy?

No. GLP-1 agonists are not recommended during pregnancy due to unknown fetal effects. The prescribing information advises discontinuing Ozempic at least 2 months before a planned pregnancy. Women who become pregnant while on the drug should stop immediately and consult their obstetrician.